GSK Plans to Sell Chronic Hepatitis B Drug in China Through Sino ...

GSK cuts deal with Sino to broaden reach of hepatitis B drug

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.

GSK plans to sell chronic hepatitis B drug in China through Sino ...

GSK enlists local aid for Chinese rollout of hep B drug

GSK has partnered Sino Biopharm to make the most of the Chinese launch of hepatitis B drug bepirovirsen, currently under review, if approved.

GSK to sell hepatitis B drug in China through SBP Group

The post GSK to sell hepatitis B drug in China through SBP Group appeared first on European Medical Journal.

GSK partners with SBP Group to support bepirovirsen launch in China

GSK plc (LON:GSK, NYSE: GSK) has announced that it has entered into an exclusive strategic collaboration with Sino Biopharmaceutical, (SBP Group), through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), to accelerate bepirovirsen in mainland China at launch. Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B (CHB) under priority regulatory review in China. CTTQ is a market leader in hepatitis B i…